Latest Breaking News On - Sense therapeutics - Page 17 : comparemela.com

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomCompany investigational new drugPrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdEuropean unionEuropean medicines agencyNeurosense therapeuticsSense therapeuticsInvestigational new drugOrphan drug designationMassachusetts general hospitalNeuron derived exosomesHealth care amp hospitalsMedical pharmaceuticals

Neurosense Therapeutics (NRSN) Receives FDA Clearance of IND for its ALS Phase 2b Study

Neurosense Therapeutics (NRSN) Receives FDA Clearance of IND for its ALS Phase 2b Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Company investigational new drugEuropean unionEuropean medicines agencyDrug administrationNeurosense therapeutics ltdSense therapeuticsInvestigational new drugOrphan drug designation

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesSan diegoUnited kingdomClearwater beachNiva russek blumShiran zimriFerenc tracikAmyotrophic lateral sclerosis consortiumNeurosense head of scientific programResearch ambassadorsInternational symposiumPrnewswire neurosense therapeutics ltdNeurosense therapeutics ltdHot topicSociety for neuroscience sfnNeals peace committee

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomNedira salzman frenkelNiva russek blumPrnewswire neurosense therapeutics ltdNeurosense vp business developmentNeurosense therapeutics ltdSense therapeuticsPartnering conference

NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

New yorkUnited statesUnited kingdomCombination therapies as frontline solutionsEuropean medicines agencyDrug administrationNeurosense therapeutics ltdNeurosense therapeuticsOpening bell ceremonyNasdaq stock marketBen noonTherapy summitNasdaq marketsiteTimes squareIndu navarAssistive novel tool